mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian
ACTIVE_NOT_RECRUITING
Status
Conditions
- BRCA1 Mutation Carrier
- BRCA2 Mutation Carrier
- Endometrial Adenocarcinoma
- Estrogen Receptor Negative
- HER2/Neu Negative
- High Grade Ovarian Serous Adenocarcinoma
- Progesterone Receptor Negative
- Recurrent Breast Carcinoma
- Recurrent Fallopian Tube Carcinoma
- Recurrent Ovarian Carcinoma
- Recurrent Primary Peritoneal Carcinoma
- Recurrent Uterine Corpus Carcinoma
- Stage III Uterine Corpus Cancer AJCC v7
- Stage IV Breast Cancer AJCC v6 and v7
- Stage IV Uterine Corpus Cancer AJCC v7
- Triple-Negative Breast Carcinoma
Interventions
- DRUG: Capivasertib
- OTHER: Laboratory Biomarker Analysis
- DRUG: Olaparib
- OTHER: Pharmacological Study
- DRUG: Vistusertib
Sponsor
M.D. Anderson Cancer Center
Collaborators